<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">IJMPCERO</journal-id><journal-title-group><journal-title>International Journal of Medical Physics, Clinical Engineering and Radiation Oncology</journal-title></journal-title-group><issn pub-type="epub">2168-5436</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ijmpcero.2019.82006</article-id><article-id pub-id-type="publisher-id">IJMPCERO-91400</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject><subject> Physics&amp;Mathematics</subject></subj-group></article-categories><title-group><article-title>
 
 
  Dosimetric Comparison of Integral Radiation Dose: Anisotropic Analytical Algorithm and Acuros XB in Breast Radiotherapy
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Aydin</surname><given-names>Cakir</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Zuleyha</surname><given-names>Akgun</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>Istanbul Memorial Hospital, Istanbul, Turkey</addr-line></aff><aff id="aff1"><addr-line>Istanbul Bilgi University, Istanbul, Turkey</addr-line></aff><pub-date pub-type="epub"><day>26</day><month>03</month><year>2019</year></pub-date><volume>08</volume><issue>02</issue><fpage>57</fpage><lpage>67</lpage><history><date date-type="received"><day>4,</day>	<month>February</month>	<year>2019</year></date><date date-type="rev-recd"><day>23,</day>	<month>March</month>	<year>2019</year>	</date><date date-type="accepted"><day>26,</day>	<month>March</month>	<year>2019</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  The impact of the difference between Anisotropic Analytical Algorithm (AAA) and Acuros XB (AXB) in breast radiotherapy is not clearly due to different uses and further research is required to explain this effect. The aim of this study is to investigate the contribution of calculation differences between AAA and AXB to the integral radiation dose (ID) on critical organs. Seven field intensity modulated radiotherapy (IMRT) plans were generated using with AAA and AXB algorithms for twenty patients with early stage left breast cancer after breast conserving surgery. Volumetric and dosimetric differences, as well as, the D
  <sub>mean</sub>, V
  <sub>5</sub>, V
  <sub>20</sub> doses of the left and right-sided lung, the D
  <sub>mean</sub>, V
  <sub>10</sub>, V
  <sub>20</sub>, V
  <sub>30</sub> doses of heart and the D
  <sub>mean</sub>, V
  <sub>5</sub>, V
  <sub>10</sub> doses of the contralateral breast were investigated. The mean dose (D
  <sub>mean</sub>), V
  <sub>5</sub>, V
  <sub>20</sub> doses of the left-sided lung, the D
  <sub>mean</sub>, V
  <sub>5</sub>, V
  <sub>10</sub> doses of right-sided lung, the D
  <sub>mean</sub>, V
  <sub>10</sub>, V
  <sub>20</sub>, V
  <sub>30</sub> doses of heart and the D
  <sub>mean</sub>, V
  <sub>5</sub>, V
  <sub>10</sub> doses of the contralateral breast were found to be significantly higher with AAA. In this research integral dose was also higher in the AAA recalculated plan and the AXB plan with the average dose as follows left lung 2%, heart 2%, contralateral breast 8%, contralateral lung 4% respectively. Our study revealed that the calculation differences between Acuros XB (AXB) and Anisotropic Analytical Algorithm (AAA) in breast radiotherapy caused serious differences on the stored integral doses on critical organs. In addition, AXB plans showed significantly dosimetric improvements in multiple dosimetric parameters.
 
</p></abstract><kwd-group><kwd>Anisotropic Analytical Algorithm</kwd><kwd> Acuros XB</kwd><kwd> Breast Radiotherapy</kwd><kwd> Integral Radiation Dose</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Radiotherapy contributes to reducing the risk of local recurrence after surgery in the treatment of early stage breast cancer. Because of the proximity of surrounding tissues, the chest region has a very heterogeneous structure. Because of this region that contains heterogeneous tissues such as the treatment area, skin, lung, heart, and also anatomical difficulties; breast radiotherapy is difficult to apply. Depending on the technique used during breast radiotherapy, healthy tissues can take wide place in the treatment area; thus healthy tissues in and around the treatment area can be exposed to high integral doses.</p><p>The integral dose (ID) is the volume integral of the dose stored in a medium and it is equal to multiplication of the mean dose and volume in the medium in which the radiation is applied at any doses. The integral dose is also the area under the curve of a differential dose absolute-volume histogram. It is often stated that a large number of beam and monitor units (MU) used in IMRT cause an increase in ID and that the photon rays with high energy principally reduce the ID. D’Souza et al. reported that the change in ID with four or more beams is &lt;1% as a function of the number of beams. As expected; high energy rays reduce the ID; they showed that the ID value was 1.5% - 1.7% for nasopharynx, 0.9% - 1.0% and 0.3% for the pancreas, and 0.4% for the prostate. These results showed that ID reduces with increasing tumor size for similar anatomic dimensions and the ID increases with increasing size of anatomical region for similar tumor sizes [<xref ref-type="bibr" rid="scirp.91400-ref1">1</xref>] .</p><p>The human body is a structure that shows different density due to its chemical structural elements. Hounsfield Unit (HU) mean value is −1000 HU in air, +1000 HU in bone, −50 - 100 HU in fat tissue and −500 HU in lungs. Classically, the Hounsfield Unit values obtained from computerized tomography are calculated with the decrease of radiation in tissue using tables specific to predefined density ranges, and CT data, CT calibration curves. Algorithms and dose calculation mechanisms that may include tissue composition may have different accuracy in determining the dose in each organ.</p><p>In the Eclipse 13.0 treatment planning system (Varian Medical Systems, Palo Alto, CA), the Anisotropic Analytical Algorithm (AAA) method is commonly used for dose calculation [<xref ref-type="bibr" rid="scirp.91400-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.91400-ref3">3</xref>] [<xref ref-type="bibr" rid="scirp.91400-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.91400-ref5">5</xref>] . In the literature, there are studies reporting that the calculated doses of AAA were significantly incorrectly calculated. Near the two mediums, especially in the transition from tissue to air, it was seen that the dose was incorrectly calculated [<xref ref-type="bibr" rid="scirp.91400-ref6">6</xref>] . Recently, a new dose calculation algorithm, Acuros XB (Varian Medical Systems, Palo Alto, CA), is started to be used in clinic to correct this situation. AXB uses a complex technique to solve Linear Boltzmann Transport Equation (LBTE) and provides an accurate approach to the calculation of patient dose in heterogeneities originating entirely from lung, bone, air and different density implants [<xref ref-type="bibr" rid="scirp.91400-ref7">7</xref>] [<xref ref-type="bibr" rid="scirp.91400-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.91400-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.91400-ref10">10</xref>] . LBTE defines the macroscopic behavior of the radiation beam in the medium through which they pass.</p><p>Up to now, the effect of the difference between AAA and AXB on breast radiotherapy is not known due to different uses and further research is required to explain this effect. The difference in calculation between the two algorithms, which is affected by parameters such as the energy of the incoming beam, the field size and the electron density of the medium, reveals dose responses.</p><p>The aim of this study is to investigate the effect of the calculation differences between the AXB and AAA algorithms on the integral doses of critical organs in the radiotherapy of patients who underwent breast-conserving surgery due to breast cancer.</p></sec><sec id="s2"><title>2. Materials and Methods</title><sec id="s2_1"><title>2.1. Eclipse Treatment Planning System</title><p>Eclipse TPS 13.0 (Varian, Palo Alto, California, USA) is designed for performing KRT, IMRT, VMAT, SRS/SBRT and electron plannings. The Eclipse treatment planning system in our clinic includes Dose Volume Optimization (DVO), Plan Geometry Optimization (PGO), Progressive Resolution Optimizer (PRO), Multi-Resolution Dose Optimization (MRDC) Algorithms, Pencil Beam Convolution (PBC), Analytical Anisotropic Algorithm (AAA) and Acuros XB (AXB) dose calculation algorithms.</p></sec><sec id="s2_2"><title>2.2. Analytical Anisotropic Algorithm</title><p>The AAA dose calculation model is a 3D pencil beam and convolution superposition algorithm consisting of separate models for electrons emitted from primary photons, scattered photons, and beam modulators (primary collimator, beam straightening filter, and wedge filter). The functional forms for the basic physical quantities initiate a process by adding device properties to the account. This often leads to a noticeable reduction in the calculation time required for such algorithms. Tissue heterogeneities are added to calculation as anisotropic using photon scattering kernels of the multiple lateral direction in the 3D neighborhood. The final dose distribution is formed by superimposing the contribution of photons and electron beams. The dose behind the air gap is a little over-calculated in the AAA algorithm with an error caused by the modeling of the scattered dose.</p></sec><sec id="s2_3"><title>2.3. Acuros XB Algorithm</title><p>The Acuros XB (AXB) algorithm was developed for two strategic needs such as accuracy and speed in external photon beam treatment planning. AXB uses a complex technique to solve Linear Boltzmann Transport Equation (LBTE) and clarifies the patient dose calculation for heterogeneities originating entirely from lung, bone, air, and non-biological implants. LBTE, which is the linear form of the Boltzman Transport Equaiton (BTE) and defines the macroscopic behavior of the radiation particles, assumes that the interaction of the radiation particles in the medium is formed without interaction of each other and an external magnetic field. There are two solution approaches that try to explain LBTE. One of them is the Monte Carlo method, which does not clearly solve the commonly known LBTE and produces indirect solutions for LBTE. Second one is solving LBTE using numerical methods.</p><p>Monte Carlo and LBTE solution methods produce close results but fail to produce clear solutions, and mistakes are occured. The mistakes of Monte Carlo System are random and result from the fact that a limited number of particles are simulated. Systematic faults can occur when using Monte Carlo methodologies to expedite the solution time.</p><p>The source model of the AXB algorithm used in Eclipse TPS uses the existing AAA resource model. Within this model; there are primary photons, out-of-focus photons, contaminated electrons and scattered photons.</p><p>The AXB algorithm uses the mass density information obtained from the CT images in each voxel for dose calculation.</p></sec><sec id="s2_4"><title>2.4. Phantom Study</title><p>In order to measure the dosimetric difference between Analytical Anisotropic Algorithm and Acuros XB, measuring assembly was prepared as in <xref ref-type="fig" rid="fig1">Figure 1</xref> and the 2 mm spaced computed tomography images were taken. A 5 cm Styrofoam layer was used to obtain the air cavity (HU = −1000) in measuring assembly. CT images of the measuring device were transferred to the Eclipse TPS. The calculation was made at the calculation grid size (CGS) of 2.5 mm for the SSD: 100 cm, 10 &#215; 10 area and at 6 MV for the AAA and AXB. Dose measurement information at specified measurement points were recorded. At the same conditions, the point dose measurements were made with 0.015 cm<sup>3</sup> pin point ion chamber (PTW, Freiburg-Germany) at predetermined measuring points by being performed irradiation in Trubeam STx device.</p></sec><sec id="s2_5"><title>2.5. Treatment Planning of Patients</title><p>Planning CT scans of 20 patients with early-stage left breast cancer, after breast-conserving surgery, were used for this study (<xref ref-type="table" rid="table1">Table 1</xref>). Data were generated with patients in the supine position with one arm above the head in the breast board. For the treatment planning, the 7-field IMRT was planned with 6 MV rays of the Varian TrueBeam STx device in the Eclipse treatment planning system. Two treatment planning were made for each patient plan using AAA and AXB algorithms. The calculation grid size (CGS) of 2.5 mm was chosen for all plans to minimize errors due to calculation grid size (CGS) in treatment volume.</p><p>The median dose of target volume was 50.4 Gy in 1.8 Gy fractions (46.8 - 50.4 Gy). An additional dose of 10 Gy (200 cGy &#215; 5 fractions) was given to the lumpectomy cavity of some patients. If necessary, the conventional photon rays of 10 MV were used with 6 MV for planning. The tissue heterogeneity corrections were used in all calculations.</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Planning CT scans of 20 patients with early-stage left breast cancer, after breast-conserving surgery, were used for this study. Data were generated with patients in the supine position with one arm above the head in the breast board</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Patıent characterıstıcs</th><th align="center" valign="middle" >n = 20</th></tr></thead><tr><td align="center" valign="middle" >Mean Age (Range)</td><td align="center" valign="middle" >52 (36 - 71)</td></tr><tr><td align="center" valign="middle" >Stage 1</td><td align="center" valign="middle" >14</td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >6</td></tr><tr><td align="center" valign="middle" >Tumor Locatıon Upper Lateral</td><td align="center" valign="middle" >10</td></tr><tr><td align="center" valign="middle" >Upper Medıal</td><td align="center" valign="middle" >2</td></tr><tr><td align="center" valign="middle" >Lower Lateral</td><td align="center" valign="middle" >7</td></tr><tr><td align="center" valign="middle" >Lower Medıal</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >Tumor Subtype Invasıve Ductal</td><td align="center" valign="middle" >15</td></tr><tr><td align="center" valign="middle" >Invasıve Lobular</td><td align="center" valign="middle" >3</td></tr><tr><td align="center" valign="middle" >Papıllary</td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >Metaplastıc</td><td align="center" valign="middle" >1</td></tr></tbody></table></table-wrap></sec><sec id="s2_6"><title>2.6. Evaluation of Dose Volume Histograms</title><p>Dose volum histograms (DVH) were evaluated for RTOG target volumes and OARs of each patient plan. While the treatment of the patients was being planned, the primary dose limitation was 95.0% of the target and 95.0% of the dose prescribed for chest or chest wall was provided to be received as PTV<sub>breast</sub>. From each patient’s treatment planning; the V<sub>5</sub> Gy, V<sub>20</sub> Gy, mean (D<sub>mean</sub>) doses were calculated for the ipsilateral lung, V<sub>10</sub> Gy, V<sub>20</sub>, V<sub>30</sub> Gy and D<sub>mean</sub> for the heart, V<sub>5</sub>, V<sub>10</sub> and D<sub>mean</sub> for the contralateral breast, V<sub>5</sub>, V<sub>10</sub> and D<sub>mean</sub> doses for the contralateral lung. Besides all these; Body-PTV doses which are not in the RTOG criteria were calculated. V<sub>5</sub> and V<sub>20</sub> doses were calculated separately for both algorithms, and small dose-volume responses of algorithms were investigated.</p></sec></sec><sec id="s3"><title>3. Results and Discussion</title><sec id="s3_1"><title>3.1. Evaluation of Phantom Measurements</title><p>In the measuring assembly shown in <xref ref-type="fig" rid="fig1">Figure 1</xref> which we prepared to demonstrate the differences in calculation between Analytical Anisotropic Algorithm and Acuros XB, the difference in dose between AAA and TPS was found to be 4% in A, which is the first dose measurement point after 5 cm air cavity, 7.8% in B, which is the second dose measurement point, and 9.5% in C.</p><p>Similarly; with AXB at the same measuring points, we achieved a difference of 1% at point A, 1.8% at point B and 3% at point C.</p></sec><sec id="s3_2"><title>3.2. Evaluation of Dose-Volume Histograms</title><p>The dosimetric results for the treatment plan of 20 breast cancer patients formed using two different algorithms, are shown in <xref ref-type="table" rid="table2">Table 2</xref>. PTV<sub>breast</sub> minimum, PTV<sub>breast</sub> D<sub>mean</sub>, PTV<sub>breast</sub> D<sub>95%</sub> doses; V<sub>5</sub> Gy, V<sub>20</sub> Gy and D<sub>mean</sub> doses for the contralateral lung; V<sub>10</sub> Gy, V<sub>20</sub>, V<sub>30</sub> Gy and D<sub>mean</sub> doses for the heart; V<sub>5</sub>, V<sub>10</sub> and D<sub>mean</sub> doses for the contralateral breast; V<sub>5</sub>, V<sub>10</sub> and D<sub>mean</sub> doses for the contralateral lung are shown in <xref ref-type="table" rid="table2">Table 2</xref>.</p><p>In <xref ref-type="table" rid="table2">Table 2</xref>; V<sub>5</sub> and V<sub>20</sub> doses are shown separately for both algorithms by calculating the Body-PTV doses, which are not in the RTOG criteria.</p><p>Dose-Volume Histogram (DVH) for a patient calculated using the AAA and AXB dose algorithms is shown in <xref ref-type="fig" rid="fig2">Figure 2</xref>. There was a difference of 13% between the PTV<sub>breast</sub> Dmin doses calculated by the AAA and AXB algorithms (p &lt; 0.05). This may be related to the fact that the PTV<sub>breast</sub> volume was calculated as high by the AAA algorithm although the PTV<sub>breast</sub> volume was removed by 0.5 cm from the skin. There was no significant difference between the PTV<sub>D95%</sub> dosescalculated by the AAA and AXB algorithms (p &gt; 0.05).</p><p>There was a significant difference between the V<sub>5</sub>, V<sub>20</sub> and D<sub>mean</sub> doses calculated by AXB and AAA algorithms for the left side lung (p &lt; 0.05). V<sub>5</sub>, V<sub>20</sub> and D<sub>mean</sub> doses of the left side lung are higher in all AAA plans than the dosimetric results of the AXB plans.</p><p>There was a significant difference between the V<sub>10</sub>, V<sub>20</sub>, V<sub>30</sub> and D<sub>mean</sub> doses of the heart in all the plans of the AAA and AXB algorithms (p &lt; 0.05).</p><p><xref ref-type="fig" rid="fig3">Figure 3</xref> shows comparison of dose distribution calculated using AAA and AXB dose calculation algorithms for a patient early-stage left breast cancer. The same 7 field IMRT plan recalculated using the AXB dose calculation algorithm (for the same patient, with the same dose scale).</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> PTV<sub>breast</sub> D<sub>min</sub>: The minimum dose of PTV<sub>breast</sub> volume, PTV<sub>breast</sub> D<sub>mean</sub>: The mean dose of PTV<sub>breast</sub> volume, PTV<sub>breast</sub> D<sub>95%</sub>: The dose prescribed to the 95% isodose line for the PTV<sub>breast</sub>, V<sub>5</sub>: % Volume receiving dose of 5 Gy, V<sub>10</sub>: % Volume receiving dose of 10 Gy, V<sub>20</sub>: % Volume receiving dose of 20 Gy, V<sub>30</sub>: % Volume receiving dose of 30 Gy, Body-PTV: The volume remaining after the removal of the PTV volume from the total body volume</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >AAA Dose(cGy) Ort &#177; SD</th><th align="center" valign="middle" >AXB Dose(cGy) Ort &#177; SD</th><th align="center" valign="middle" >p value</th><th align="center" valign="middle" >Integral Dose AAA (cGy*cm<sup>3</sup>) Ort &#177; SD</th><th align="center" valign="middle" >Integral Dose AXB (cGy*cm<sup>3</sup>) Ort &#177; SD</th><th align="center" valign="middle" >p value</th></tr></thead><tr><td align="center" valign="middle" >PTV<sub>breast</sub> D<sub>min</sub></td><td align="center" valign="middle" >3006 &#177; 125</td><td align="center" valign="middle" >2600 &#177; 105</td><td align="center" valign="middle" >0.001</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >PTV<sub>breast</sub> D<sub>mean</sub></td><td align="center" valign="middle" >5400 &#177; 125</td><td align="center" valign="middle" >5310 &#177; 108</td><td align="center" valign="middle" >0.021</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >PTV<sub>breast</sub> D<sub>95% </sub></td><td align="center" valign="middle" >4870 &#177; 15</td><td align="center" valign="middle" >4810 &#177; 12</td><td align="center" valign="middle" >0.034</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Left Lung D<sub>mean</sub></td><td align="center" valign="middle" >1185 &#177; 12</td><td align="center" valign="middle" >1133 &#177; 8</td><td align="center" valign="middle" >0.003</td><td align="center" valign="middle" >1,265,561 &#177; 418</td><td align="center" valign="middle" >1,245,455 &#177; 287</td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >Left Lung (V<sub>5</sub>)</td><td align="center" valign="middle" >79 &#177; 3</td><td align="center" valign="middle" >72 &#177; 3</td><td align="center" valign="middle" >0.004</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Left Lung (V20)</td><td align="center" valign="middle" >14.9 &#177; 2</td><td align="center" valign="middle" >14.2 &#177; 2.3</td><td align="center" valign="middle" >0.002</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Heart D<sub>mean</sub></td><td align="center" valign="middle" >619 &#177; 4.2</td><td align="center" valign="middle" >604 &#177; 2.4</td><td align="center" valign="middle" >0.002</td><td align="center" valign="middle" >318.785 &#177; 344</td><td align="center" valign="middle" >312.605 &#177; 225</td><td align="center" valign="middle" >0.002</td></tr><tr><td align="center" valign="middle" >Heart (V<sub>10</sub>)</td><td align="center" valign="middle" >8.7 &#177; 2.1</td><td align="center" valign="middle" >8.5 &#177; 1.8</td><td align="center" valign="middle" >0.004</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Heart (V<sub>20</sub>)</td><td align="center" valign="middle" >4.8 &#177; 1.2</td><td align="center" valign="middle" >4.5 &#177; 1.1</td><td align="center" valign="middle" >0.003</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Heart (V<sub>30</sub>)</td><td align="center" valign="middle" >3.8 &#177; 1</td><td align="center" valign="middle" >3.4 &#177; 1</td><td align="center" valign="middle" >0.004</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Contralateral breast D<sub>mean</sub></td><td align="center" valign="middle" >202 &#177; 2.3</td><td align="center" valign="middle" >185 &#177; 2.2</td><td align="center" valign="middle" >0.003</td><td align="center" valign="middle" >205.838 &#177; 25</td><td align="center" valign="middle" >188.515 &#177; 24</td><td align="center" valign="middle" >0.003</td></tr><tr><td align="center" valign="middle" >Contralateral breast (V<sub>5</sub>)</td><td align="center" valign="middle" >4.7 &#177; 2.2</td><td align="center" valign="middle" >3.3 &#177; 2.1</td><td align="center" valign="middle" >0.001</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Contralateral breast (V<sub>10</sub>)</td><td align="center" valign="middle" >0.6 &#177; 0.2</td><td align="center" valign="middle" >0.7 &#177; 0.1</td><td align="center" valign="middle" >0.034</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Contralateral Lung D<sub>mean</sub></td><td align="center" valign="middle" >289 &#177; 4</td><td align="center" valign="middle" >277 &#177; 2.1</td><td align="center" valign="middle" >0.001</td><td align="center" valign="middle" >362.406 &#177; 25</td><td align="center" valign="middle" >347.358 &#177; 18</td><td align="center" valign="middle" >0.002</td></tr><tr><td align="center" valign="middle" >Contralateral Lung (V<sub>5</sub>)</td><td align="center" valign="middle" >12 &#177; 1.1</td><td align="center" valign="middle" >11.4 &#177; 1.1</td><td align="center" valign="middle" >0.004</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Contralateral Lung (V<sub>10</sub>)</td><td align="center" valign="middle" >0.70 &#177; 0.1</td><td align="center" valign="middle" >0.62 &#177; 0.1</td><td align="center" valign="middle" >0.003</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Body-PTV (V<sub>5</sub>)</td><td align="center" valign="middle" >24.2 &#177; 1.6</td><td align="center" valign="middle" >24 &#177; 1.7</td><td align="center" valign="middle" >0.250</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Body-PTV (V<sub>20</sub>)</td><td align="center" valign="middle" >10.8 &#177; 1.1</td><td align="center" valign="middle" >10.9 &#177; 1.2</td><td align="center" valign="middle" >0.320</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>When D<sub>mean</sub> doses of the contralateral lung doses were evaluated, there was a significant difference between AAA plans and AXB plans (p &lt; 0.05). There was also a significant difference between the doses of V<sub>5</sub> and V<sub>10</sub> in the contralateral lung (p &lt; 0.05).</p><p>There was a significant difference between the D<sub>mean</sub>, V<sub>5</sub> and V<sub>10</sub> doses of the contralateral breast (p &lt; 0.05).</p><p>Finally; in our study comparing the V<sub>5</sub> and V<sub>20</sub> doses for Body-PTV, it was found that there was no significant relationship between AAA plans and AXB plans (p &gt; 0.05)</p><p>Huang et al. showed that the calculation grid size (CGS) was related to the dose estimation in their studies of the lung streotactic radiotherapy (SBRT) planning [<xref ref-type="bibr" rid="scirp.91400-ref11">11</xref>] . To reduce this effect in our study, all plans for both algorithms were calculated at 2.5 mm CGS.</p><p>In a planning study performed for nasopharyngeal cancers by Kan et al., they reported that a lower dose between 3% and 6% was obtained with AXB on critical organs compared to AAA [<xref ref-type="bibr" rid="scirp.91400-ref12">12</xref>] .</p><p>Chung and Mittauer showed that CGS was effective on dose estimation for head and neck treatments [<xref ref-type="bibr" rid="scirp.91400-ref13">13</xref>] [<xref ref-type="bibr" rid="scirp.91400-ref14">14</xref>] . Ong et al. reported that the 1.0 mm CGS performed a more accurate dose calculation than the 2.5 mm CGS in AAA calculations [<xref ref-type="bibr" rid="scirp.91400-ref15">15</xref>] .</p><p>In our dosimetric phantom study, we detected that there was a 3% compliance was between the depth dose measurement and Acuros AXB algorithm. However, we found there was a dose difference of 9.5% between the depth dose measurement and AAA algorithm.</p><p>In the phantom study with 6 MV photon rays by Bush et al., they showed that there was difference of 4.5% between AXB and Monte Carlo algorithms in the transition from air to tissue and this difference increased to 13% between AAA and Monte Carlo algorithms [<xref ref-type="bibr" rid="scirp.91400-ref16">16</xref>] . In parallel with this study, Kan et al. found that there was a difference of 3% between the measurement and AXB algorithm in the transition from air to tissue and this difference reached 10% with AAA algorithm (12). In the rando phantom study study developed for head and neck treatments by Han et al., they found the maximum difference between measurement and calculation as 4.6% for AAA and 3.6% for AXB [<xref ref-type="bibr" rid="scirp.91400-ref17">17</xref>] .</p><p>In a study comparing the treatment plans of deep inspriation condition and free-breathing breast patients by Fogliata et al., they showed that Anisotropic Analytical Algorithm calculated a 1.6% more dose in PTV than Acuros XB [<xref ref-type="bibr" rid="scirp.91400-ref18">18</xref>] .</p><p>Padmanaban et al. compared the AAA and AXB algorithms using 3D Conformal and Rapid Arc techniques in the treatment of osefagus cancers and they found that the AXB algorithm determined a low dose in PTV (0.5 - 1.3 Gy) according to AAA. They showed that the low dose in PTV obtained for AXB was not related to the technique used [<xref ref-type="bibr" rid="scirp.91400-ref19">19</xref>] .</p></sec></sec><sec id="s4"><title>4. Conclusions</title><p>The most remarkable side of our study is that the dose of breast tissue that starts immediately after the skin was calculated as higher with the AAA algorithm. There was difference of 13% between AAA plans and AXB plans in determining PTV min dose. The AAA algorithm calculated a higher dose than should be in the build-up area between air and tissue. The higher dose should be in PTV, and will increase the maximum dose effect in the hot dose regions as a result of the normalization of the plan to the treatment dose.</p><p>The integral dose (ID) is the volume integral of the dose stored in a medium and it is equal to multiplication of the mean dose (D<sub>mean</sub>) and volume in the medium. Often, the large number of beams and high irradiation times used in the IMRT cause an increase in the ID and this increase in the ID is prevented by using high energy photon rays. In the literature, there is no study comparing integral doses of healthy organs between AAA and AXB algorithms.</p><p>Our study revealed that the calculation differences between Acuros XB (AXB) and Anisotropic Analytical Algorithm (AAA) in breast radiotherapy caused serious differences on the stored integral doses on critical organs.</p><p>As a result; in the region where we are pushing critical dose limits such as skin, lung, heart, and contralateral breast, the administering of breast radiotherapy and the accuracy of dose delivery are very difficult due to both anatomical and different density tissues. In addition to very different tissue densities within the treatment area, many devices that increase the dosimetric uncertainty associated with the patient stabilizing devices found that the outside treatment area affects the dose in the patient. It should be kept in mind that treatment planning algorithms do not yet have the ability to accurately calculate the dose in air-tissue transition zones.</p></sec><sec id="s5"><title>Conflicts of Interest</title><p>None.</p></sec><sec id="s6"><title>Cite this paper</title><p>Cakir, A. and Akgun, Z. (2019) Dosimetric Comparison of Integral Radiation Dose: Anisotropic Analytical Algorithm and Acuros XB in Breast Radiotherapy. International Journal of Medical Physics, Clinical Engineering and Radiation Oncology, 8, 57-67. https://doi.org/10.4236/ijmpcero.2019.82006</p></sec></body><back><ref-list><title>References</title><ref id="scirp.91400-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">D’Souza, W.D. and Rosen, I.I. (2003) Nontumor Integral Dose Variation in Conventional Radiotherapy Treatment Planning. Medical Physics, 30, 2065-2071.  
https://doi.org/10.1118/1.1591991</mixed-citation></ref><ref id="scirp.91400-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Tillikainen, L., Siljamaki, S., Helminen, H., Alakuijala, J. and Pyyry, J. (2007) Determination of Parameters for a Multiple-Source Model of Megavoltage Photon Beams Using Optimization Methods. Physics Medicine in Biology, 52, 1441-1467.  
https://doi.org/10.1088/0031-9155/52/5/015</mixed-citation></ref><ref id="scirp.91400-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Breitman, K., Rathee, S., Newcomb, C., Murray, B., Robinson, D., Field, C., et al. (2007) Experimental Validation of the Eclipse AAA Algorithm. Journal of Applied Clinical Medical Physics, 10, 76-92.</mixed-citation></ref><ref id="scirp.91400-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Tillikainen, L., Helminen, H., Torsti, T., Siljamaki, S., Alakuijala, J., Pyyry, J. and Ulmer, W. (2008) A 3D Pencil-Beam-Based Superposition Algorithm for Photon Dose Calculation in Heterogeneous Media. Physics in Medicine and Biology, 53, 3821-3839. https://doi.org/10.1088/0031-9155/53/14/008</mixed-citation></ref><ref id="scirp.91400-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Van Esch, A., Tillikainen, L., Pyykkonen, J., Tenhunen, M., et al. (2006) Testing of the Analytical Anisotropic Algorithm for Photon Dose Calculation. Medical Physics, 33, 4130-4148. https://doi.org/10.1118/1.2358333</mixed-citation></ref><ref id="scirp.91400-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Robinson, D.M. (2008) Inhomogeneity Correction and the Analytical Anisotropic Algorithm. Journal of Applied Clinical Medical Physics, 9, 112-122.  
https://doi.org/10.1120/jacmp.v9i2.2786</mixed-citation></ref><ref id="scirp.91400-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Vassiliev, O., Wareing, T., McGhee, J., Failla, G., Salehpour, M. and Mourtada, F. (2010) Validation of a New Grid-Based Blotzmann Equation Solver for Dose Calculation in Radiotherapy with Photon Beams. Physics Medicine in Biology, 55, 581-598.</mixed-citation></ref><ref id="scirp.91400-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Hoffmann, L., Jorgensen, M., Muren, L. and Petersen, J. (2012) Clinical Validation of the Acuros XB Photon Dose Calculation Algorithm, a Grid-Based Boltzmann Equation Solver. Acta Oncologica. 51, 376-385.  
https://doi.org/10.3109/0284186X.2011.629209</mixed-citation></ref><ref id="scirp.91400-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Fogliata, A., Nicolini G., Clivio, A., Vanetti, E. and Cozzi, L. (2011) Dosimetric Evaluation of Acuros XB Advanced Dose Calculation Algorithm in Heterogeneous Media. Radiation Oncology, 6, 82. https://doi.org/10.1186/1748-717X-6-82</mixed-citation></ref><ref id="scirp.91400-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Han, T., Mikell, J., Salehpour, M. and Mourtada, F.(2011) Dosimetric Comparison of Acuros XB Deterministic Radiation Transport Method with Monte Carlo and Model-Based Convolution Methods in Heterogeneous Media. Medical Physics, 38, 2651-2664. https://doi.org/10.1118/1.3582690</mixed-citation></ref><ref id="scirp.91400-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Huang, B., Wu, L.L., Pei, X.L. and Chen, C.Z. (2015) Dose Calculation of Acuros XB and Anisotropik Analytical Algorithm in Lung Stereotactic Body Radiotherapy Treatment with Flattening Filter Free Beams and Potential Role of Calculation Grid Size. Radiation Oncology, 10, 53. https://doi.org/10.1186/s13014-015-0357-0</mixed-citation></ref><ref id="scirp.91400-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Kan, M., Leung, L. and Yu, P. (2012) Verification and Dosimetric Impact of Acuros XB Algorithm on Intensity Modulated Stereotactic Radiotherapy for Locally Persistent Nasopharyngeal Carcinoma. Medical Physics, 39, 4705-4714.  
https://doi.org/10.1118/1.4736819</mixed-citation></ref><ref id="scirp.91400-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Chung, H., Jin, H., Palta, J., Suh, T.S. and Kim, S. (2006) Dose Variations with Varying Calculation Grid Size in Head and Neck IMRT. Physics Medicine in Biology, 51, 4841-4856.</mixed-citation></ref><ref id="scirp.91400-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Mittauer, K., Lu, B., Yan, G., Kahler, D., Gopal, A., Amdur, R., et al. (2013) A Study of IMRT Planning Parameters on Planning Efficiency, Delivery Efficiency, and Plan Quality. Medical Physics, 40, Article ID: 061704. https://doi.org/10.1118/1.4803460</mixed-citation></ref><ref id="scirp.91400-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Ong, C.L., Cuijpers, J.P., Senan, S., Slotman, B.J. and Verbakel, W.F. (2011) Impact of the Calculation Resolution of AAA for Small Fields and RapidArc Treatment Plans. Medical Physics, 38, 4471-4479. https://doi.org/10.1118/1.3605468</mixed-citation></ref><ref id="scirp.91400-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Bush, K., Gagne, I.M., Zavgorodni, S., Ansbacher, S. and Beckham, W. (2011) Dosimetric Validation of Acuros XB with Monte Carlo Methods for Photon Dose Calculations. Medical Physics, 38, 2208-2221. https://doi.org/10.1118/1.3567146</mixed-citation></ref><ref id="scirp.91400-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Han, T., Mourtada, F., Kisling, K., Mikell, J., Followill, D. and Howell, R. (2012) Experimental Validation of Deterministic Acuros XB Algorithm for IMRT and VMAT Dose Calculation with Radiological Physics Center’s Head and Neck Phantom. Medical Physics, 39, 2193-2202. https://doi.org/10.1118/1.3692180</mixed-citation></ref><ref id="scirp.91400-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Fogliata, A., Nicolini, G., Clivio, A., Vanetti, E. and Cozzi, L. (2011) On the Dosimetric Impact of Inhomogeneity Management in the Acuros XB Algorithm for Breast Treatment. Radiation Oncology, 6, 103.  
https://doi.org/10.1186/1748-717X-6-103</mixed-citation></ref><ref id="scirp.91400-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Padmanaban, S., Warren, S., Walsh, A., Partridge, M. and Hawkins, A. (2014) Comparison of Acuros (AXB) and Anisotropic Analytical Algorithm (AAA) for Dose Calculation in Treatment of Oesophageal Cancer: Effects on Modelling Tumour Control Probability. Radiation Oncology, 9, 286.</mixed-citation></ref></ref-list></back></article>